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The balance between the benefits and the risks of any medical
treatment, action for prevention, or diagnostic procedure lies
at the heart of any clinical decision. In line with this, the
European Medicines Agency (EMA) recently set up a series
of Good Pharmacovigilance Practices to reinforce procedures
for surveillance and reporting of adverse events with
authorised medical products [1]. These new regulations are
currently being applied throughout all EU member states. In
this context, the safety of all centrally registered drugs is
closely monitored by the EMA through a new committee,
the Pharmacovigilance Risk Assessment Committee
(PRAC), which was launched in October 2012. The proce-
dures include regular submission of periodic safety update
reports (PSURs).
Naturally, treatments in osteoporosis are no exception to
these regulations. In November 2012, the PSUR for strontium
ranelate, which encompassed a number of new randomised
clinical trials, included an updated assessment of the overall
safety of the treatment and was submitted to the PRAC in
accordance with the regulatory schedule. The overall safety
analyses showed an increased cardiovascular risk in patients
treated with strontium ranelate [2]. This ongoing process has
led to a label change, and, in order to mitigate the cardiovas-
cular risk, strontium ranelate is now contraindicated in pa-
tients with a history of cardiovascular disease, i.e. in patients
with a history of ischaemic heart disease, peripheral artery
disease, and/or cerebrovascular disease and in those with
uncontrolled hypertension. As a precaution, patients should
now be evaluated for cardiovascular risk before starting treat-
ment with strontium ranelate and at regular intervals during
treatment.
In the light of these procedures, the results of two new
studies that recently became available are published together
in this issue of Osteoporosis International [3, 4]. Both con-
stitute retrospective observational studies conducted in data-
bases of electronic healthcare records and were set up to
analyse the cardiovascular risk associated with the prescrip-
tion of strontium ranelate in real-life clinical practice in the
UK and in Denmark.
The two studies have contrasting sources of data and study
design. The study presented by Cooper et al. [3] is a nested
case–control study that combines longitudinal primary care
data from the UK (Clinical Practice Research Datalink) with
external National Health Service-linked datasets that provide
information on the cause of death and hospitalisation.
Abrahamsen et al. [4] report a traditional cohort study in the
Danish National Prescription Database, which links data be-
tween national registries for dispensed prescriptions,
hospitalisations, and causes of death for fatalities in Denmark.
The results of the studies are consistent on three points.
First, observational data do not indicate that the use of stron-
tium ranelate was associated with a significant increase in
myocardial infarction. Cooper et al. compared the risk of
ischaemic cardiac events in postmenopausal osteoporotic
women who were currently receiving treatment with stron-
tium ranelate—or had received it in the past—with the risk in
those who had never received strontium ranelate [3]. Current
use or past use of strontium ranelate was not associated with
any significant increase in the risk for three cardiovascular
events: first myocardial infarction, hospitalisation with myo-
cardial infarction, or cardiovascular death. In their study,
Abrahamsen calculated the incidence of myocardial infarction
in men and postmenopausal women [4] and reported that the
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risk for myocardial infarction was not significantly elevated,
though they did find a very borderline result for stroke and
cardiovascular death and a significant increase in risk for all-
cause mortality.
Second, both studies highlighted substantial differences in
patient profile of users of strontium ranelate compared with
users of other osteoporosis treatments. Indeed, it appears that
strontium ranelate patients are generally older, and—as would
be expected for an older population—they have more severe
osteoporosis and a longer duration of disease. They also have
more co-morbidities, notably those related to elevated cardio-
vascular risk, such as cardiac failure (22 % in the Danish
study), peripheral vascular disease (6 %), and cerebrovascular
disease (11 %), with a combined prevalence of ischaemic
heart disease, peripheral vascular disease, and cerebrovascular
disease of 19 % in women and 30 % in men. The cases of
ischaemic cardiac events in the UK study were also at sub-
stantially higher risk compared with the controls, with higher
rates of history of hospitalisation for myocardial infarction
(12 versus 4 %), ischaemic heart disease (71 versus 24 %),
peripheral artery disease (18 versus 7 %), and cerebrovascular
disease (23 versus 15 %). This is a significant finding for
clinical practice: the majority of cases of myocardial infarction
occurred in patients who would not be treated with the agent
according to the new contraindications for strontium ranelate.
Third, while each study has its merits and limitations—and
both are highly robust—neither study managed to properly
address the major challenge of the potential channelling bias
by which more fragile or severe patients being switched to
strontium ranelate. Clearly, further research is warranted with
appropriate handling of the remaining bias for a more com-
plete evaluation of risk.
All osteoporosis treatments have their own inherent bene-
fits and risks, and a clear-cut assessment of the benefit/risk
ratio is important when they are to be used long term [5–7].
The role of the clinician is to select the best treatment for the
patient’s profile and individual therapeutic objective, which
should remain the prevention of osteoporotic fracture [8]. By
strictly applying the new contraindications for strontium
ranelate, we can hope to achieve our primary goal of treating
disease, preventing osteoporotic fracture, while markedly re-
ducing the risk for side effects.
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